Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P54098
UPID:
DPOG1_HUMAN
Alternative names:
Mitochondrial DNA polymerase catalytic subunit; PolG-alpha
Alternative UPACC:
P54098; Q8NFM2; Q92515
Background:
DNA polymerase subunit gamma-1, also known as PolG-alpha, plays a crucial role in mitochondrial DNA replication. This enzyme's association with mitochondrial DNA ensures the maintenance of the mitochondrial genome, vital for cellular energy production.
Therapeutic significance:
Given its pivotal role in mitochondrial function, DNA polymerase subunit gamma-1 is linked to various mitochondrial disorders, including Progressive external ophthalmoplegia and Leigh syndrome. Understanding the role of DNA polymerase subunit gamma-1 could open doors to potential therapeutic strategies for these debilitating conditions.